上海海顺新型药用包装材料股份有限公司 2023 年第一季度报告 上海海顺新型药用包装材料股份有限公司 2023 年第一季度报告 | | | 上海海顺新型药用包装材料股份有限公司 2023 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第一季度报告是否经过审计 □是 否 1 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | | --- | --- | --- | --- | --- | | | | | （%） | | | 营业收入（元） | 260,137,982.34 | 231,871,055.84 | | 12.19% | | 归属于上市公司股 ...

Financial Performance - The company's operating revenue for 2022 was ¥1,012,601,235.55, representing an increase of 18.18% compared to ¥856,857,795.71 in 2021[20]. - The net profit attributable to shareholders for 2022 was ¥102,461,491.00, a decrease of 2.09% from ¥104,645,765.20 in 2021[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥93,649,802.79, down 7.88% from ¥101,661,160.24 in 2021[20]. - The basic earnings per share for 2022 was ¥0.53, a decline of 17.19% compared to ¥0.64 in 2021[20]. - The total assets at the end of 2022 were ¥2,305,352,111.13, reflecting a growth of 1.82% from ¥2,264,050,337.46 at the end of 2021[20]. - The net assets attributable to shareholders increased by 5.74% to ¥1,596,620,328.83 at the end of 2022 from ¥1,509,959,144.83 at the end of 2021[20]. - The cash flow from operating activities for 2022 was ¥136,957,656.04, a slight decrease of 1.92% from ¥139,639,384.21 in 2021[20]. - The company achieved a revenue of ¥1,012,601,235.55 in 2022, representing an 18.18% increase year-over-year[48]. - The net profit attributable to the listed company was ¥102,461,491.00, a decrease of 2.09% compared to the previous year[48]. - The gross profit margin for new pharmaceutical packaging materials decreased by 2.38% to 28.75%, while the gross profit margin for hard packaging increased by 2.58% to 29.12%[58]. Dividend Distribution - The company reported a profit distribution plan to distribute a cash dividend of 0.5 CNY per 10 shares (including tax) based on a total of 193,531,505 shares[3]. - The company plans to distribute a cash dividend of RMB 0.5 per 10 shares, totaling RMB 9,676,575.25 (including tax) for the fiscal year 2022[163]. - The total number of shares for the dividend distribution is based on 193,531,505 shares, with a cash dividend amounting to 100% of the total profit distribution[163]. - The company's distributable profit for the period is RMB 518,276,767.53[163]. - No bonus shares or capital reserve transfers to increase share capital are proposed for this distribution[163]. Research and Development - R&D expenses increased by 35.32% during the reporting period, reflecting the company's commitment to innovation and product development[49]. - The company is focused on developing new products such as flame-retardant polypropylene films for lithium battery packaging and moisture-proof blister packaging for pharmaceuticals[72]. - The number of R&D personnel increased by 31.76% from 85 in 2021 to 112 in 2022, representing 13.74% of the total workforce[72]. - R&D investment amounted to ¥44,490,523.83 in 2022, up 35.36% from ¥32,877,686.18 in 2021, accounting for 4.39% of operating revenue[73]. - The company emphasizes technology R&D as a key driver for growth, with a strategic focus on enhancing core competitiveness through increased R&D personnel and investment[73]. Market and Industry Outlook - The pharmaceutical packaging industry in China is projected to grow, with a market size of approximately ¥135.86 billion in 2021, reflecting a year-on-year growth of 16%[32]. - The company aims to enhance its international competitiveness and stabilize supply chains by accelerating industrial upgrades and developing new products and technologies[33]. - Future outlook includes plans to expand market presence in the pharmaceutical packaging sector, targeting a 25% increase in market share over the next two years[94]. - The company is investing in R&D for new high-barrier coating materials, with an expected launch in Q3 2023[94]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[192]. Risks and Challenges - The company faces various risks including market competition, raw material price fluctuations, and potential declines in gross margin[3]. - The company has faced significant challenges due to rising raw material prices and a shortage of core equipment, leading to increased production costs[33]. - The company is exposed to raw material price volatility risks, particularly for aluminum and petroleum derivatives, and will manage inventory and supplier relationships to mitigate these risks[110]. - The company has faced risks from industry policy adjustments, with the National Medical Products Administration implementing stricter regulations on drug packaging materials since 2016, which could impact operations if not adapted to new requirements[111]. - The company is at risk of underutilizing new production capacity if market demand or competitive dynamics change significantly, despite thorough feasibility studies conducted for new projects[113]. Corporate Governance - The company maintains independence from its controlling shareholders, ensuring separate operations in assets, personnel, finance, and business[123]. - The company emphasizes information disclosure, adhering to legal requirements and ensuring timely and accurate information dissemination[120]. - The company has established specialized committees under the board, including a strategy and investment decision-making committee, to provide professional opinions[119]. - The company has implemented a robust internal management and control system to enhance governance levels[118]. - The company has complied with all relevant laws and regulations regarding corporate governance, with no significant discrepancies noted[122]. Employee and Management - The company has increased its employee count to 815, a significant growth compared to the previous year, supporting its operational capabilities[53]. - The total remuneration paid to the board of directors, supervisors, and senior management for 2022 amounted to 5.4679 million yuan[143]. - The company has implemented a performance-based salary system, adjusting employee compensation annually based on company performance and individual contributions[156]. - The company provided restricted stock incentives to outstanding employees to enhance team cohesion and core competitiveness[157]. - The company conducted training programs for new employees, marketing personnel, and management to improve skills and adapt to new management models[158]. Environmental Responsibility - The company has implemented a comprehensive environmental protection strategy, with all pollution control facilities operating normally and no administrative penalties received for environmental issues during the reporting period[178]. - The company emphasizes green development and has invested in pollution control technology, ensuring compliance with national and local environmental regulations[178]. - The company has implemented measures to reduce carbon emissions and has continuously invested in and upgraded environmental protection facilities to comply with national regulations[179]. - The company has developed energy usage plans tailored to each subsidiary's business characteristics to improve energy efficiency and reduce waste[181]. - The company emphasizes the importance of social responsibility, aiming for a balance between economic and social benefits, and promoting sustainable development[182].

公司定于2023年4月7日（星期五）15：00-17：00在全景网举行2022 年度业绩说明会。本次业绩说明会将会采用网络远程的方式举行，投 资者可登录"全景网投资者关系互动平台"（http://ir.p5w.net） 参与本次业绩说明会。 证券代码：300501 证券简称：海顺新材 公告编号：2023-026 上海海顺新型药用包装材料股份有限公司 关于举办2022年度业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 上海海顺新型药用包装材料股份有限公司（以下简称"公司"） 于2023年3月31日在巨潮资讯网（http://www.cninfo.com.cn）披露 了2022年年度报告全文及年度报告摘要。为了更好地与广大投资者进 行交流，使投资者能够进一步了解公司的生产经营情况，公司拟举办 2022年度业绩说明会。具体安排如下： 届时，公司董事长兼总经理林武辉先生、财务负责人倪海龙先生、 独立董事王琳琳女士、董事会秘书杨高锋先生，保荐代表人姚奔先生 将出席本次业绩说明会。 为充分尊重投资者、提升交流的针对性，现就公司2022年度业绩 说明会提前 ...

编号：2016-07-01 证券代码：300501 证券简称：海顺新材 上海海顺新型药用包装材料股份有限公司 投资者关系活动记录表 | --- | --- | --- | |--------------|----------------|---------------------------------| | | | | | 投资者关系活 | ■ 特定对象调研 | □ 分析师会议 | | 动类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | ■ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称 | 西南证券 | 张汪强 | | 及人员姓名 | 西南证券 | 施跃 | | | 信诚基金 | 杨强 | | | 泰信基金 | 徐慕浩 | | | 建信基金 | 陈洁馨 | | | 财通资管 | 顾明豪 | | | 常春藤 | 冯先涛 | | | 天风证券 | 余方升 | | --- | --- | |----------------------------|------------| | | | | 华宝兴业基金 | 郎超 | ...

编号：2017-05-18 证券代码：300501 证券简称：海顺新材 上海海顺新型药用包装材料股份有限公司 投资者关系活动记录表 | --- | --- | --- | |--------------|---------------------------|------------------------------------------------------| | | | | | 投资者关系活 | □ | 特定对象调研 □分析师会议 | | 动类别 | □ | 媒体采访 □业绩说明会 | | | □ 新闻发布会 □路演活动 | | | | □ 现场参观 | | | | ■其他 （ 2017 | 年上海地区上市公司、基金公司集体接待日） | | 参与单位名称 | 网上投资者，基金公司 | | | 及人员姓名 | | | | 时间 | 2017 年 5 月 18 | 日 | | 地点 | 上海衡山北郊宾馆 | | | 上市公司接待 | 董事会秘书 童小晖 | | | 人员姓名 | 证券事务代表 钱燕 | | | 投资者关系活 | 1. 公司在主会场通过全景 | IR 互动平台和网上投资者远程交流。 | | ...

Group 1: Product Development and Market Position - The company is focusing on developing alternative packaging materials to replace glass bottles, which are high in energy consumption and production costs [2] - Recent advancements in plastic processing technology have allowed the company to create effective packaging solutions that are more efficient and cost-effective than glass [2] - The company has successfully developed several liquid pharmaceutical packaging solutions and aims to extend its offerings further [3] Group 2: Financial Performance and Growth Potential - The company’s subsidiaries are expected to achieve a reasonable profit margin of 12%-15%, indicating significant room for improvement [3] - The pharmaceutical packaging industry has a large market potential, with leading companies in developed countries generating revenues in the billions [4] - The company emphasizes technological innovation and equipment upgrades to improve efficiency and quality, which is crucial for maintaining a profit margin above 10% [5] Group 3: Industry Trends and Competitive Landscape - The domestic pharmaceutical packaging industry is fragmented, with over 1,500 companies, suggesting a future trend towards consolidation [4] - The company recognizes the competitive landscape and aims to enhance its comprehensive competitiveness to advance its business [4] - The company is strategically targeting innovative clients and integrated raw material companies to expand its customer base [6] Group 4: International Market Strategy - The company had plans for local network development overseas, but these have been impacted by the pandemic, particularly in Europe [7] - Southeast Asia remains a promising market for future expansion [7]

证券代码：300501 证券简称：海顺新材 上海海顺新型药用包装材料股份有限公司 投资者关系活动记录表 编号：2020-001 | --- | --- | --- | --- | |----------------|----------------------------|-----------------------------------------------------|---------------------------| | | | | | | | ☑ | 特定对象调研 □分析师会议 | | | 投资者关系活动 | □ | 媒体采访 □业绩说明会 | | | | □ | 新闻发布会 □路演活动 | | | 类别 | □ 现场参观 | | | | | □ 其他：线上交流活动 | | | | 参与单位名称及 | 兴全基金 -李君 | 交银施罗德基金-徐嘉辰 华泰柏瑞基金-张 | | | 人员姓名 | 弘、彭邦泰 招商基金 | -李世伟 | 天治基金管理有限公司-尹维 | | | | 国 银华基金-王翔、孙昊阳、孙昊天 银河基金-金寿鹏 兴 | | | | 银基金-林德涵 风和亚洲基金 | -李树荣 ...

编号：2020-002 证券代码：300501 证券简称：海顺新材 上海海顺新型药用包装材料股份有限公司 投资者关系活动记录表 | --- | --- | --- | |----------------|------------------------------|---------------------------------------| | | | | | | ☑ 特定对象调研 □分析师会议 | | | 投资者关系活动 | □ 媒体采访 □业绩说明会 | | | | □ 新闻发布会 □路演活动 | | | 类别 | □ 现场参观 | | | | □ 其他：线上交流活动 | | | | 华安基金 - | 钱坤、张亮 财通基金-杨爱琳 | | 参与单位名称及 | 诺安基金-唐晨 | 富国基金-曾新杰、王园园 | | 人员姓名 | | 中银证券-杨志威、鞠龙 安信证券-吕科佳 | | | 北京泓澄投资-丁力佳 南土资产 | - 范自彬 | | 时间 | 2020 年 7 月 27 日 | 15:30-17:00 | | 地点 | 公司会议室 | | | 上市公司接待人 | 董事长、总经理、董秘——林武辉 | ...